Zai Lab Shares Climb Over 5% on Positive Preclinical Data for ZL-1503

Stock News04-20

Zai Lab (09688) rose more than 5%, with a gain of 5.64% to HK$19.3 at the time of writing. The trading volume reached HK$120 million. On April 18, the company released new preclinical data for ZL-1503, indicating that its internally developed IL-13/IL-31Rα bispecific antibody may provide sustained suppression of severe itching and inflammation caused by atopic diseases. The findings were presented during a poster session at the IMMUNOLOGY2026 conference in Boston, Massachusetts, further supporting ZL-1503's potential as a first-in-class treatment for moderate-to-severe atopic dermatitis and other diseases driven by IL-13 and IL-31. Zai Lab initiated the first-in-human Phase 1/1b clinical study for ZL-1503 in December 2025, with clinical data expected to be announced in the second half of 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1180735240?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-20 09:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1180735240","market":"fut","top_or_hot":-1,"title":"Zai Lab Shares Climb Over 5% on Positive Preclinical Data for ZL-1503","media":"Stock News","content":"<p>Zai Lab (09688) rose more than 5%, with a gain of 5.64% to HK$19.3 at the time of writing. The trading volume reached HK$120 million. On April 18, the company released new preclinical data for ZL-1503, indicating that its internally developed IL-13/IL-31Rα bispecific antibody may provide sustained suppression of severe itching and inflammation caused by atopic diseases. The findings were presented during a poster session at the IMMUNOLOGY2026 conference in Boston, Massachusetts, further supporting ZL-1503's potential as a first-in-class treatment for moderate-to-severe atopic dermatitis and other diseases driven by IL-13 and IL-31. Zai Lab initiated the first-in-human Phase 1/1b clinical study for ZL-1503 in December 2025, with clinical data expected to be announced in the second half of 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zai Lab Shares Climb Over 5% on Positive Preclinical Data for ZL-1503</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZai Lab Shares Climb Over 5% on Positive Preclinical Data for ZL-1503\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-20 09:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Zai Lab (09688) rose more than 5%, with a gain of 5.64% to HK$19.3 at the time of writing. The trading volume reached HK$120 million. On April 18, the company released new preclinical data for ZL-1503, indicating that its internally developed IL-13/IL-31Rα bispecific antibody may provide sustained suppression of severe itching and inflammation caused by atopic diseases. The findings were presented during a poster session at the IMMUNOLOGY2026 conference in Boston, Massachusetts, further supporting ZL-1503's potential as a first-in-class treatment for moderate-to-severe atopic dermatitis and other diseases driven by IL-13 and IL-31. Zai Lab initiated the first-in-human Phase 1/1b clinical study for ZL-1503 in December 2025, with clinical data expected to be announced in the second half of 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1180735240","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1180735240","pubTimestamp":1776649820,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Zai Lab (09688) rose more than 5%, with a gain of 5.64% to HK$19.3 at the time of writing. The trading volume reached HK$120 million. On April 18, the company released new preclinical data for...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4585":"ETF&股票定投概念","09688":"再鼎医药","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK4548":"巴美列捷福持仓","BK1588":"回港中概股","BK4526":"热门中概股","BK4588":"碎股","VXUS":"国际股票ETF-Vanguard","BK1161":"生物科技","BK1574":"生物医药B类股","BK4531":"中概回港概念","ZLAB":"再鼎医药"},"translate_title":"ZL-1503临床前数据积极，再鼎医药股价上涨超过5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09688":1,"ZLAB":1,"VXUS":1},"content_text":"Zai Lab (09688) rose more than 5%, with a gain of 5.64% to HK$19.3 at the time of writing. The trading volume reached HK$120 million. On April 18, the company released new preclinical data for ZL-1503, indicating that its internally developed IL-13/IL-31Rα bispecific antibody may provide sustained suppression of severe itching and inflammation caused by atopic diseases. The findings were presented during a poster session at the IMMUNOLOGY2026 conference in Boston, Massachusetts, further supporting ZL-1503's potential as a first-in-class treatment for moderate-to-severe atopic dermatitis and other diseases driven by IL-13 and IL-31. Zai Lab initiated the first-in-human Phase 1/1b clinical study for ZL-1503 in December 2025, with clinical data expected to be announced in the second half of 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1180735240","isCrawlerRequest":true}